238 related articles for article (PubMed ID: 16575474)
1. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
2. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
3. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
4. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
Styczynski J; Kurylak A; Wysocki M
Anticancer Res; 2005; 25(3B):2253-8. PubMed ID: 16158972
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
7. Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
Janiszewska H; Styczynski J; Kolodziej B; Wysocki M; Haus O
Ann Hematol; 2009 Dec; 88(12):1193-8. PubMed ID: 19352661
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia.
Styczyński J; Wysocki M; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk A; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Neoplasma; 2002; 49(3):178-83. PubMed ID: 12098004
[TBL] [Abstract][Full Text] [Related]
9. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
10. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia in childhood: treatment, results and prognostic factors.
Advani SH; Giri NK; Pai SK; Nair CN; Kurkure PA; Tapan SK; Gopal R; Nadkarni KS; Pai VR; Muzumdar AT
Indian J Cancer; 1989 Sep; 26(3):180-8. PubMed ID: 2630428
[TBL] [Abstract][Full Text] [Related]
12. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
13. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
[TBL] [Abstract][Full Text] [Related]
14. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL.
Hundsdoerfer P; Dietrich I; Schmelz K; Eckert C; Henze G
Pediatr Blood Cancer; 2010 Aug; 55(2):260-6. PubMed ID: 20582956
[TBL] [Abstract][Full Text] [Related]
15. Circumvention of glucocorticoid resistance in childhood leukemia.
Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
[TBL] [Abstract][Full Text] [Related]
16. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
17. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?
Styczynski J; Wysocki M
J Clin Oncol; 2004 Mar; 22(5):963-4. PubMed ID: 14990658
[No Abstract] [Full Text] [Related]
18. Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children.
Koga Y; Matsuzaki A; Suminoe A; Hattori H; Kanemitsu S; Hara T
Pediatr Blood Cancer; 2005 Aug; 45(2):121-7. PubMed ID: 15704223
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.
Styczynski J; Toporski J; Wysocki M; Debski R; Chybicka A; Boruczkowski D; Wachowiak J; Wojcik B; Kowalczyk J; Gil L; Balwierz W; Matysiak M; Krawczuk-Rybak M; Balcerska A; Sonta-Jakimczyk D
Anticancer Res; 2007; 27(3B):1547-51. PubMed ID: 17595774
[TBL] [Abstract][Full Text] [Related]
20. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]